Zhang Z, et al. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Front Med. 2019;13:57–68.
Article
PubMed
Google Scholar
Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017;6(2):196–211.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pandey D, et al. Mediastinal staging for non-small cell lung cancer revisited. It is being done under aegis of ICON and Lung cancer consortium Asia. Indian J Cancer. 2017;54(1):68–72.
Article
CAS
PubMed
Google Scholar
Nishie K, et al. Anamorelin for advanced non-small-cell lung cancer with cachexia: systematic review and meta-analysis. Lung Cancer. 2017;112:25–34.
Article
PubMed
Google Scholar
Wu HH, et al. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer. Ann Surg Oncol. 2013;20(Suppl 3):S336–47.
Article
PubMed
Google Scholar
Goldberg SB, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24:1872–80.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hradilova N, et al. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. PLoS ONE. 2017;12(2):e0171539.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hubbeling HG, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2018;13:550–8.
Article
PubMed
Google Scholar
Zeltsman M, et al. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Transl Res. 2017;187:1–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hersom M, Jorgensen JT. Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Ther Drug Monit. 2018;40(1):9–16.
CAS
PubMed
Google Scholar
Hunter KA, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Mol Diagn Ther. 2018;22(1):1–10.
Article
PubMed Central
CAS
Google Scholar
Chae YK, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.
Article
PubMed
PubMed Central
Google Scholar
Gonzalez-Cao M, et al. Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer (Auckl). 2015;6:55–70.
CAS
Google Scholar
Larsen TV, Hussmann D, Nielsen AL. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer. Cancer Commun (Lond). 2019;39(1):30.
Article
Google Scholar
Lim TS, et al. PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology. 2016;5(3):e1085146.
Article
PubMed
CAS
Google Scholar
Li W, et al. Exosomes derived from Rab27aoverexpressing tumor cells elicit efficient induction of antitumor immunity. Mol Med Rep. 2013;8(6):1876–82.
Article
CAS
PubMed
Google Scholar
Fatima F, Nawaz M. Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer. 2015;34(12):541–53.
CAS
PubMed
Google Scholar
Besse B, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008.
Article
PubMed
CAS
Google Scholar
Upham JW, Xi Y. Dendritic cells in human lung disease: recent advances. Chest. 2017;151(3):668–73.
Article
PubMed
Google Scholar
Son KJ, et al. Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw. 2016;16(1):75–84.
Article
PubMed
PubMed Central
Google Scholar
Chae CS, Teran-Cabanillas E, Cubillos-Ruiz JR. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. Cancer Immunol Immunother. 2017;66(8):969–77.
Article
CAS
PubMed
Google Scholar
Shang N, et al. Dendritic cells based immunotherapy. Am J Cancer Res. 2017;7(10):2091–102.
CAS
PubMed
PubMed Central
Google Scholar
Schneider Thomas, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol. 2011;6:1162–8.
Article
PubMed
Google Scholar
Li J, et al. Myeloid-derived suppressor cells accumulate among myeloid cells contributing to tumor growth in matrix metalloproteinase 12 knockout mice. Cell Immunol. 2018;327:1–12.
Article
PubMed
CAS
Google Scholar
Sass SN, et al. Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. Cancer Immunol Immunother. 2018;67(6):873–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ohnuki H, et al. Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-beta signaling to drive malignant progression. Cancer Res. 2014;74(7):2038–49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ruez R, et al. Dendritic cell migration toward CCL21 gradient requires functional Cx43. Front Physiol. 2018;9:288.
Article
PubMed
PubMed Central
Google Scholar
Gwin K, et al. Differential requirement for Hoxa9 in the development and differentiation of B, NK, and DC-lineage cells from Flt3+ multipotential progenitors. BMC Immunol. 2013;14:5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234(1):45–54.
Article
CAS
PubMed
Google Scholar
Giordano D, et al. Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses. J Leukoc Biol. 2011;89(3):443–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharma MD, et al. Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c(+)CD103(+) monocytic antigen-presenting cells in tumors. Immunity. 2018;48(1):91–106 e6.
Article
PubMed
PubMed Central
CAS
Google Scholar
Narita M, et al. Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA. Med Oncol. 2009;26(4):429–36.
Article
CAS
PubMed
Google Scholar
Hammad H, Lambrecht BN. Lung dendritic cell migration. Adv Immunol. 2007;93:265–78.
Article
CAS
PubMed
Google Scholar
Bedoui S, Heath WR. Kruppel-ling of IRF4-dependent DCs into two functionally distinct DC subsets. Immunity. 2015;42(5):785–7.
Article
CAS
PubMed
Google Scholar
Grajales-Reyes GE, et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8alpha(+) conventional DC clonogenic progenitor. Nat Immunol. 2015;16(7):708–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yan J, et al. FGL2 promotes tumor progression in the CNS by suppressing CD103(+) dendritic cell differentiation. Nat Commun. 2019;10(1):448.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kenna T, et al. CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver. Cancer Immunol Immunother. 2007;56(4):563–72.
Article
CAS
PubMed
Google Scholar
Lavin Y, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–65 e17.
Article
CAS
Google Scholar
Masten BJ, et al. Characterization of myeloid and plasmacytoid dendritic cells in human lung. J Immunol. 2006;177(11):7784–93.
Article
CAS
PubMed
Google Scholar
Faith A, et al. Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am J Respir Cell Mol Biol. 2007;36(3):360–7.
Article
CAS
PubMed
Google Scholar
Jongbloed SL, et al. Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol. 2009;182(2):963–8.
Article
CAS
PubMed
Google Scholar
Alegre ML. DC metabolism controls lung T cell polarization. Am J Transplant. 2018;18(2):285.
Article
PubMed
Google Scholar
Macri C, et al. Dendritic cell subsets. Semin Cell Dev Biol. 2017;84:11–21.
Article
PubMed
CAS
Google Scholar
Liu Y, Cao X. Intratumoral dendritic cells in the anti-tumor immune response. Cell Mol Immunol. 2015;12(4):387–90.
Article
PubMed
PubMed Central
Google Scholar
Roberts EW, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR45 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salmon H, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pyfferoen L, et al. The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. Oncoimmunology. 2017;6(1):e1253655.
Article
PubMed
CAS
Google Scholar
Dutertre CA, Wang LF, Ginhoux F. Aligning bona fide dendritic cell populations across species. Cell Immunol. 2014;291(1–2):3–10.
Article
CAS
PubMed
Google Scholar
Alculumbre S, et al. Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease association. Semin Cell Dev Biol. 2018;86:24–35.
Article
PubMed
CAS
Google Scholar
Manz MG. Plasmacytoid dendritic cells: origin matters. Nat Immunol. 2018;19:652.
Article
CAS
PubMed
Google Scholar
Pinto A, Morello S, Sorrentino R. Lung cancer and toll-like receptors. Cancer Immunol Immunother. 2011;60(9):1211–20.
Article
CAS
PubMed
Google Scholar
Conrad C, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012;72(20):5240–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pedroza-Gonzalez A, et al. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology. 2015;4(6):e1008355.
Article
PubMed
PubMed Central
CAS
Google Scholar
Smirnov A, et al. Sphingosine 1-phosphate- and C–C chemokine receptor 2-dependent activation of CD4(+) plasmacytoid dendritic cells in the bone marrow contributes to signs of sepsis-induced immunosuppression. Front Immunol. 2017;8:1622.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liu C, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008;118(3):1165–75.
CAS
PubMed
PubMed Central
Google Scholar
Sorrentino R, et al. Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J Immunol. 2010;185(8):4641–50.
Article
CAS
PubMed
Google Scholar
Narusawa M, et al. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Cancer Immunol Res. 2014;2(6):568–80.
Article
CAS
PubMed
Google Scholar
Rega A, et al. Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide-stimulated lung tumor-bearing mice. J Immunol. 2013;190(5):2391–402.
Article
CAS
PubMed
Google Scholar
Shi W, et al. Level of plasmacytoid dendritic cells is increased in non-small cell lung carcinoma. Tumour Biol. 2014;35(3):2247–52.
Article
CAS
PubMed
Google Scholar
Sorrentino R, et al. Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1alpha in an AIM2 inflammasome-dependent manner. Am J Pathol. 2015;185(11):3115–24.
Article
CAS
PubMed
Google Scholar
Zhong H, et al. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer. 2014;134(11):2633–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Spallanzani RG, et al. Regulatory dendritic cells restrain NK cell IFN-gamma production through mechanisms involving NKp46, IL-10, and MHC class I-specific inhibitory receptors. J Immunol. 2015;195(5):2141–8.
Article
CAS
PubMed
Google Scholar
Zhang C, et al. The effect of semimature dendritic cell and the levels of Treg on transplantation tolerance of hepatocytes differentiated from mouse embryonic stem cell. Zhonghua Yi Xue Za Zhi. 2017;97(4):259–64.
CAS
PubMed
Google Scholar
Spary LK, et al. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology. 2014;3(9):e955331.
Article
PubMed
PubMed Central
Google Scholar
Pardee AD, Shi J, Butterfield LH. Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol. 2014;193(11):5723–32.
Article
CAS
PubMed
Google Scholar
Zong J, et al. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016;65(7):821–33.
Article
CAS
PubMed
Google Scholar
Goc J, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74(3):705–15.
Article
CAS
PubMed
Google Scholar
Caronni N, et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 2018;78:1685–99.
Article
CAS
PubMed
Google Scholar
Li R, et al. STAT3 and NF-kappaB are simultaneously suppressed in dendritic cells in lung cancer. Sci Rep. 2017;7:45395.
Article
CAS
PubMed
PubMed Central
Google Scholar
Galvez-Cancino F, et al. A short hairpin RNA-based adjuvant targeting NF-kappaB repressor IkappaBalpha promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination. Vaccine. 2017;35(33):4148–54.
Article
CAS
PubMed
Google Scholar
Xue W, et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 2011;1(3):236–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
McLoed AG, et al. Neutrophil-derived IL-1beta impairs the efficacy of NF-kappaB inhibitors against lung cancer. Cell Rep. 2016;16(1):120–32.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schneider T, et al. Immune response after radiofrequency ablation and surgical resection in nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2016;28(2):585–92.
Article
PubMed
Google Scholar
Luo D, et al. B7-H3 regulates lipid metabolism of lung cancer through SREBP1-mediated expression of FASN. Biochem Biophys Res Commun. 2017;482(4):1246–51.
Article
CAS
PubMed
Google Scholar
He CS, et al. Astragaloside IV enhances cisplatin chemosensitivity in non-small cell lung cancer cells through inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221–9.
Article
CAS
PubMed
Google Scholar
Zhang G, et al. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer. 2009;66(2):245–9.
Article
PubMed
Google Scholar
Fatima F, Nawaz M. Vesiculated long non-coding RNAs: offshore packages deciphering trans-regulation between cells, cancer progression and resistance to therapies. Noncoding RNA. 2017;3(1):10.
PubMed Central
Google Scholar
Pyfferoen L, et al. Lung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level. Int J Cancer. 2014;135(12):2868–77.
Article
CAS
PubMed
Google Scholar
Luo LH, et al. Tim3/galectin-9 alleviates the inflammation of TAO patients via suppressing Akt/NF-kB signaling pathway. Biochem Biophys Res Commun. 2017;491(4):966–72.
Article
CAS
PubMed
Google Scholar
Chiba S, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nobumoto A, et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol. 2009;130(3):322–30.
Article
CAS
PubMed
Google Scholar
Cheng DE, et al. Involvement of IL10 and granulocyte colonystimulating factor in the fate of monocytes controlled by galectin1. Mol Med Rep. 2014;10(5):2389–94.
Article
CAS
PubMed
Google Scholar
Kuo PL, et al. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol. 2011;186(3):1521–30.
Article
CAS
PubMed
Google Scholar
Chow MT, Moller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol. 2012;22(1):23–32.
Article
CAS
PubMed
Google Scholar
Michaud HA, et al. Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity. Oncoimmunology. 2014;3(9):e955684.
Article
PubMed
PubMed Central
Google Scholar
Liu QY, et al. High mobility group box 1 protein suppresses T cell-mediated immunity via CD11c(low)CD45RB(high) dendritic cell differentiation. Cytokine. 2011;54(2):205–11.
Article
CAS
PubMed
Google Scholar
Niki M, et al. New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl). 2017;8:91–9.
CAS
Google Scholar
Ma Y, et al. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Tumori. 2017;104:338–43.
Article
Google Scholar
Aguilar-Cazares D, et al. Relationship of dendritic cell density, HMGB1 expression, and tumor-infiltrating lymphocytes in non-small cell lung carcinomas. Appl Immunohistochem Mol Morphol. 2014;22(2):105–13.
Article
CAS
PubMed
Google Scholar
Smolarczyk R, et al. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp (Warsz). 2012;60(5):391–9.
Article
CAS
Google Scholar
Zhang Y, et al. Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother. 2017;67:353–66.
Article
PubMed
CAS
Google Scholar
Ning Y, et al. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. Immunol Lett. 2018;199:36–43.
Article
CAS
PubMed
Google Scholar
Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328–32.
Article
CAS
PubMed
Google Scholar
Cornel AM, et al. Strategies to genetically modulate dendritic cells to potentiate anti-tumor responses in hematologic malignancies. Front Immunol. 2018;9:982.
Article
PubMed
PubMed Central
CAS
Google Scholar
Grees M, et al. Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncoimmunology. 2018;7(7):e1445457.
Article
PubMed
PubMed Central
Google Scholar
Dobrovolskiene N, et al. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Vaccine. 2018;36(29):4171–80.
Article
CAS
PubMed
Google Scholar
Arai R, et al. Lipid accumulation in peripheral blood dendritic cells and anticancer immunity in patients with lung cancer. J Immunol Res. 2018;2018:5708239.
Article
PubMed
PubMed Central
CAS
Google Scholar
Obleukhova I, et al. Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer. Oncol Lett. 2018;15(1):1297–306.
PubMed
Google Scholar
Song H, et al. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC. Int Immunopharmacol. 2017;52:197–202.
Article
CAS
PubMed
Google Scholar
Geskin LJ, et al. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018;28(3):211–21.
CAS
PubMed
PubMed Central
Google Scholar
Mookerjee A, Graciotti M, Kandalaft LE. Correction: a cancer vaccine with dendritic cells differentiated with GM-CSF and IFNalpha and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. Bioimpacts. 2019;9(1):65.
Article
PubMed
PubMed Central
Google Scholar
Xiao L, et al. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017;6(6):e1319044.
Article
PubMed
PubMed Central
Google Scholar
Jiang T, et al. Immunotherapy with dendritic cells modified with tumor-associated antigen gene demonstrates enhanced antitumor effect against lung cancer. Transl Oncol. 2017;10(2):132–41.
Article
PubMed
PubMed Central
Google Scholar
Baspinar Y, et al. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer. Int J Pharm. 2019;566:149–56.
Article
CAS
PubMed
Google Scholar
Chen ZQ, Huang LS, Zhu B. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. Dis Markers. 2018;2018:9845123.
PubMed
PubMed Central
Google Scholar
Aldrich M, et al. SOCS1 downregulation in dendritic cells promotes memory T-cell responses. Vaccine. 2008;26(8):1128–35.
Article
CAS
PubMed
Google Scholar
Ge C, et al. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer. 2017;17(1):884.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lee JM, et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res. 2017;23(16):4556–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lynch DH. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo. Crit Rev Immunol. 1998;18(1–2):99–107.
Article
CAS
PubMed
Google Scholar
Chakravarty PK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 1999;59(24):6028–32.
CAS
PubMed
Google Scholar
Saito H, et al. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther. 2017;24(7):289–96.
Article
CAS
PubMed
Google Scholar
Li AW, et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018;17:528.
Article
CAS
PubMed
PubMed Central
Google Scholar
Somaiah N, et al. First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-19-1025.
Article
PubMed
PubMed Central
Google Scholar
Chiappori AA, et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immunother. 2019;68(3):517–27.
Article
CAS
PubMed
Google Scholar
Nadafi R, et al. Dendritic cell migration to skin-draining lymph nodes is controlled by dermatan sulfate and determines adaptive immunity magnitude. Front Immunol. 2018;9:206.
Article
PubMed
PubMed Central
CAS
Google Scholar
Imai K, et al. Inhibition of dendritic cell migration by transforming growth factor-beta1 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res. 2012;31:3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang H, et al. Potential involvement of monocyte chemoattractant protein (MCP)-1/CCL2 in IL-4-mediated tumor immunity through inducing dendritic cell migration into the draining lymph nodes. Int Immunopharmacol. 2003;3(5):627–42.
Article
CAS
PubMed
Google Scholar
Chen CL, et al. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncoimmunology. 2018;7(4):e1417721.
Article
PubMed
PubMed Central
Google Scholar
Ge Y, et al. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013;336(2):253–9.
Article
CAS
PubMed
Google Scholar